Our understanding of alcohol craving, both as a cause for chronic abuse and
relapse and as a target for intervention, has been refined significantly i
n recent years. For example, craving experienced during alcohol withdrawal
may be mediated by gamma -aminobutyric acid (GABA) and glutamate receptor m
echanisms, whereas the memory of the rewarding aspects of alcohol may be me
diated by dopamine, opiate, and glutamate systems. Therefore, pharmacologic
treatments for alcohol dependence may be targeted to numerous pathways. Th
is article will discuss animal and clinical studies of the opioid antagonis
ts (primarily naltrexone), acamprosate, and disulfiram. The side effects an
d treatment recommendations for each drug will also be reviewed.